William Blair analyst Myles Minter has maintained their bullish stance on OVID stock, giving a Buy rating today.
Myles Minter has given his Buy rating due to a combination of factors related to Ovid Therapeutics’ promising pipeline and recent developments. The company is advancing its OV329 program, a next-generation GABA-AT inhibitor, with a comprehensive update expected in the third quarter. This update will include data on safety, tolerability, and biomarker impacts, which are crucial for supporting its anti-seizure potential. Notably, OV329 has shown no serious adverse events and lacks retinal accumulation, a significant improvement over existing treatments.
Minter also highlights the initiation of first-in-human studies for OV350, a KCC2 activator, which has shown potential in addressing a range of conditions from seizures to psychosis. The broad applications and early positive results from OV350 further strengthen Ovid’s position. Although the OV888 program remains on pause, the strategic evaluation reflects the company’s careful approach to clinical development. These factors collectively underpin Minter’s optimistic outlook and Buy rating for Ovid Therapeutics.
